MedCap : Presentation MedCap Q4 2021

Q4 Presentation 2021

We create value and contribute to improved quality of life in Life Science

2

MedCap | An active investor in Life Science companies

MedTech Business Area

Sales by Segment (MSEK)		Geographies
	5%
35%	21%			Sweden
		Nordic
916			53%
			Europe
65%	21%
		RoW

Specialty Pharma Business Area

Employees

361

Listed on Stockholm

Nasdaq Mid Cap

MedTech Specialty Pharma

3

Highlights Q4

• Sales growth
• EBITDA increased by 27% excluding one- time effects of 3.3 mSEK
• Both business areas, MedTech and Specialty Pharma, contributed to sales and EBITDA growth
• Strong margin (24% EBITDA-margin (22%) after excluding one-time effects)
• As previous year Q4 is a strong quarter

Q4 2021

Net Sales	257.9	+14%
(MSEK)
EBITDA	66.5	+34%
(MSEK)
EBITDA-	26%	+4.0 ppt
margin

4

Sales and EBITDA by quarter

Net sales per quarter (MSEK)										+14%
300																			233		258
250									200			211	206	209		227	223	202
					183			188	186		175
200			152		173	166	160
		139
150		120
100
50
0
	Q1	Q2	Q3	Q1	*	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3		Q4	Q1	Q2	Q3	Q4
		Q2
		17/18			18				19				20
EBITDA per quarter (MSEK)										+34%		67
70
60
															50			50
50																	46
								41					41				41
									36		38		35
40											31
											27
30					22
					20
			17		19	17
20		14
	12
10
0
Q1	Q2	Q3	Q1	*	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3		Q4	Q1	Q2	Q3	Q4
		Q2
		17/18			18				19				20

• Q3 2017/18: two months
• IFRS16 incl. from Q1 2019

	Q4	YTD
Net Sales	+14%	+12%
growth
EBITDA	+34%	+29%
growth
EBITDA-	26%*	22%*
margin

Impact quarter comparison

• MedCap acquisition: Multi-ply (from 29 Oct 2020)
• One-timeeffects of 3.3 mSEK

* Q4 24% and YTD 20% adjusted for one-time effects